Abstract: The adherence of protective and/or decorative paints to polyphenylene ether resins, alone, or combined with high impact strength polystyrene resins, is markedly improved by adding a high impact rubber modified terpolymer resin comprising units of a non-polar aromatic monovinyl compound, e.g., styrene, a polar monovinyl compound, e.g., acrylonitrile, acrylic acid, methacrylic acid, maleic anhydride, etc., and a diene rubber, e.g., butadiene.

Abstract: The invention provides a wound dressing comprising a pad of soft polyurethane foam one surface layer of which is hydrophilic and a backing layer of which is hydrophobic and a sheet or strip of a soft conformable polyether foam having an adhesive on one surface thereof. The surface of said pad opposite the hydrophobic layer is secured to said sheet or strip by said adhesive and said sheet or strip overlaps said pad to enable the pad to be secured in position with said hydrophilic layer in contact with a wound by means of said adhesive.

Abstract: Testosterone is administered transdermally through nonscrotal skin in a manner that mimics in amount and profile the natural production of testosterone in young adult healthy males. The testosterone is administered to the skin from a matrix which contains testosterone at subsaturation concentration and a permeation enhancer.

Abstract: Vitamin E acts to enhance and improve the effect upon oral administration of coronary active vasodilators and/or blood circulation-promoters. The new use and new agents containing vitamin E are described.

Abstract: A pressure-sensitively adhering multilayer medicinal preparation comprises a pressure-sensitively adhering macromolecular substance layer and a polymer layer adjacent thereto and the drug and adjuvant incorporated in said preparation each can migrate from the layer of its original incorporation into the other, said adjuvant being capable of increasing absorption of the drug. In such preparation, the drug amount per unit volume can be increased.

Abstract: Transdermal absorption dosage units have been developed for treatment of postmenopausal syndrome which comprise a backing layer, an adjoining adhesive polymer layer in which at least minimum effective daily doses of an estrogen is microdispersed. Presently preferred is use of the natural estrogen, 17-beta-estradiol, or ethinyl estradiol or combinations thereof together with an amount of a natural progestogen or a progestin to minimize any potential side effects. The units use bioacceptable adhesive and polymers. An additional polymer layer in intimate contact with the estrogen-containing layer can be used. Also, a separating layer can optionally be used in making the dosage units, which separate the two adhesive polymer layers, which permits estrogen transmission from the first adhesive polymer layer during treatment. Dosage units are provided which transdermally deliver at least minimum daily doses of the estrogen for at least one day or for multiple days, such as for one week.

Abstract: A diffusional drug delivery device is described which can provide for delayed onset of therapeutic effect and for delivery of the therapeutic agent in predetermined temporal patterns at optimum rates. Delay means are provided between the agent reservoir and the surface through which the agent is released by diffusion to delay the release of agent at a therapeutic rate for predetermined times after application. Suitable means include a delay membrane disposed between the releasing surface and the agent reservoir which membrane is preferably free of undissolved agent and/or is initially impermeable to the agent and thereafter becomes permeable. One or more agent chambers defined by one or more of such membranes may be provided, whereby agents are released in a predetermined temporal pattern at optimal release rates.

Abstract: A pharmacological composition for soft capsules, containing a polyprenyl compound having the formula (1) and a surfactant and/or an unsaturated aliphatic acid, has improved absorbability. ##STR1## wherein n represents 1 to 3.

Abstract: The present invention relates to tablets of the type which contain a homogeneous dispersion of an active principle based on salbutamol or on one of its derivatives in a hydrophilic matrix, ensuring:in vitro, long-term release of the active principle, which is constant and independent of pH, over a time interval of about 12 hours,in vivo, uptake kinetics of the active principle by the organism of zero order over a time interval of 6 hours, the said matrix containing at least one swelling agent and a diluent in a weight ratio of swelling agent/diluent lying between 0.2 and 0.6, and being preferably equal to about 0.4.The present invention also covers the process for the preparation of these tablets.

Abstract: The present invention provides a method of reducing or preventing skin irritation of a weak base drug by inhibiting the accumulation of the drug in the lysosomes. The drug is irritating to humans, i.e., the drug is susceptible to inducing skin or mucosa irritation in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Irritation reduction or prevention is induced by coadministering to the skin or mucosa of the human:(a) a therapeutically effective amount of a weak base drug which is irritating to humans, at a therapeutically effective rate over a predetermined period of time; and(b) an effective amount of an agent capable of inhibiting the lysosomal uptake of the drug to reduce or prevent irritation to the skin or mucosa.

Abstract: The association of physiologically dosed vitamin A and of various active principles having a therapeutical activity such as mineral and/or organic sulphur, associated or not with biologically active principles such as dead yeast, lactobacilli, gastro-intestinal germs or others, dead or attenuated, characterized in that the vitamin A dose per capsule for the adult is at most 1700 I.U.

Abstract: Oral pharmaceutical compositions in unit dosage form suitable for swallowing (especially capsules) comprising a safe and effective amount of a soluble bismuth-containing pharmaceutical agent (preferably a pharmaceutically-acceptable salt suitable for oral co-administration of bismuth and an H.sub.2 receptor blocking anti-secretory agent), and optionally one or more pharmaceutically-acceptable carrier materials, wherein the packing density of the dosage unit is less than about 1 g/ml.

Abstract: Percutaneous or trans-mucosal absorption enhancer comprising of a terpeneketone and preparation containing thereof. Preferably, the preparation contains a percutaneous or trans-mucosal absorption enhancer in an amount of 0.01-20 weight % of the preparation. In preparing the preparation, a terpeneketone is dissolved and emulsified in a water soluble organic solvent which is medically allowable.

Abstract: The present invention relates to a therapeutic system for the transdermal or transmucous administration of active substances via an impermeable backing layer, a reservoir which at least partially comprises active substance, is double-layered and consists of separate parts, and a protective layer, whereby the two reservoir members(a) are positioned substantially parallely on top of each other,(b) are separated from each other by a removable intermediate layer being impermeable to the active substances of said reservoir members,(c) either comprise active substance or auxiliary agents or both at concentrations not corresponding to the distribution equilibrium.

Abstract: The present invention relates to a transdermal therapeutic system for the combined administration of oestrogens and gestagens. The therapeutic system consists of:(1) a closed outer layer which is impermeable to the constituents of the active ingredient formulation,(2) a reservoir containing essential constituents of the active ingredient formulation and, optionally, a membrane,(3) an adhesive layer and(4) a peel-off protective layer on the adhesive layer.The system contains an oestrogen derivative in combination with a synthetic gestagen, and an agent that enhances percutaneous absorption.

Abstract: A microporous, cellulosic coating useful in combination with osmotically controlled drug delivery devices is disclosed. In one embodiment, this coating results from application to core tablets of a coating dispersion comprised of a synthetic latex formed by emulsification of cellulosic polymers stabilized by surfactants, containing a water-soluble pore forming agent and a plasticizer.

Abstract: The invention relates to an apparatus for the controlled delivery or release of nitroglycerin to the human or animal skin, preferably in plaster form with a nitroglycerin-impermeable backing layer, a one or multiple-part reservoir containing a pressure sensitive adhesive nitroglycerin in uniform or irregular distribution and optionally a removable protective layer impermeable for nitroglycerin, the reservoir being produced using hol melt pressure sensitive adhesives with a processing temperature of 40.degree. to 80.degree. C., preferably 40.degree. to 60.degree. C. and in particularly preferred manner 40.degree. to 45.degree. C., a process for the production thereof and the use of the apparatus for therapeutic purposes in human and veterinary medicine.

Abstract: A dispenser is disclosed for delivering a beneficial ionophore to an animal. The dispenser comprises (1) a semipermeable housing defining an internal space, (2) at least one composition comprising an ionophore and a pharmaceutically acceptable carrier in the space, (3) an expandable hydrophilic composition in the space, (4) a dense member in the space, and (5) at least one exit passageway in the housing for delivering the ionophore from the dispenser.

Abstract: A method for the treatment of gastrointestinal disease through a transdermally administered antisecretory agent. Antisecretory agents useful for transdermal administration are substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles and omeprazole.

Abstract: Transdermal administration of dexmedetomidine, the dextrorotatory isomer of medetomidine, is described. The method involves sedating a patient by administering dexmedetomidine to a predetermined area of skin at an administration rate and for a time period effective to achieve the desired level of sedation. A therapeutic system for transdermally administering the drug is also provided. The therapeutic system is in the form of a skin patch which is a laminated composite of a backing layer, an optional anchor adhesive layer, a contact adhesive layer, and one or more additional layers.